Zobrazeno 1 - 10
of 732
pro vyhledávání: '"Andexanet Alfa"'
Publikováno v:
Thrombosis Journal, Vol 22, Iss 1, Pp 1-6 (2024)
Abstract Bleeding events in patients receiving direct oral anticoagulation (DOAC) can be life-threatening even at therapeutic DOAC plasma concentrations, as anticoagulation impairs hemostasis and should therefore be identified immediately after hospi
Externí odkaz:
https://doaj.org/article/eb36fcba42a248edb1f97d98f2e7309d
Publikováno v:
eJHaem, Vol 5, Iss 4, Pp 829-832 (2024)
Abstract Andexanet alfa is a recombinant, modified factor Xa (FXa) molecule that is used for the reversal of the anticoagulant effect of oral anti‐FXa anticoagulants in patients with major haemorrhage. Here, we present a case of an 85‐year‐old
Externí odkaz:
https://doaj.org/article/3115ed11d813400a849f62c7a64d9094
Autor:
Paul P. Dobesh, Craig I. Coleman, Mark Danese, Eva Lesén, Raymond C. Chang, Onivefu Odelade, Gregory J. Fermann
Publikováno v:
Journal of the American College of Emergency Physicians Open, Vol 5, Iss 6, Pp n/a-n/a (2024)
Abstract Objectives This study describes clinical characteristics and management strategies for patients with factor Xa (FXa) inhibitor–related traumatic non‐intracranial bleeds who were treated with andexanet alfa or four‐factor prothrombin co
Externí odkaz:
https://doaj.org/article/9993a5739f4645a68899f3e1583c75d5
Facial trauma with life-threatening bleeding treated by andexanet alfa administration: A case report
Autor:
Yasunori Shirakawa, Naoto Jingami, Yoshitaka Ishiguro, Takuma Minami, Ken Shinozuka, Tomoyuki Yunoki, Shigeru Ohtsuru
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e36922- (2024)
Recently, anticoagulant reversal has become a treatment option for life-threatening bleeding, especially in intracranial hemorrhage. Although evidence of the beneficial efficacy of andexanet alfa accumulates in cases of intracranial hemorrhage, littl
Externí odkaz:
https://doaj.org/article/80c13a9bf30f4dd7a906934af0078673
Autor:
John Vellek, Omar H. Tarawneh, Syed Faraz Kazim, Oluwafemi P. Owodunni, Sophia Arbuiso, Smit Shah, Alis J. Dicpinigaitis, Meic H. Schmidt, Rohini G. McKee, Richard Miskimins, Fawaz Al-Mufti, Christian A. Bowers
Publikováno v:
World Neurosurgery: X, Vol 23, Iss , Pp 100367- (2024)
Externí odkaz:
https://doaj.org/article/feb332cacfbe4f68a0fc8c9bf7ccda32
Autor:
Mark Goldin, Kolton Smith, Ioannis Koulas, Tungming Leung, Mayuri Ravi, Sanjit Parhar, Sejal Shah, Kayla Floyd, Lori Ohanesian, Rachel Bain, Daniella Defonte, Kanta Ochani, Amanda Lin, Bhumi Patel, Nikolaos Tsaftaridis, Jack Jnani, Alex C. Spyropoulos
Publikováno v:
TH Open, Vol 08, Iss 02, Pp e209-e215 (2024)
Background Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Externí odkaz:
https://doaj.org/article/b4c8d7cd0de345d594f879f98c252755
Autor:
Mauricio Concha, Lizhen Xu, MacKenzie Horn, Tomoyuki Ohara, Juliet Nakamya, Jan Beyer‐Westendorf, Ashkan Shoamanesh, Alexander Cohen, Per Ladenvall, Stuart J. Connolly, Andrew M. Demchuk
Publikováno v:
Stroke: Vascular and Interventional Neurology, Vol 4, Iss 1 (2024)
Background Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor
Externí odkaz:
https://doaj.org/article/9afe5c2bf3dd4bf3923c253ead8387eb
Publikováno v:
JA Clinical Reports, Vol 9, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/ec7d8376a96a44bf91a87a4477bb7221
Autor:
Bartosz Karaszewski, Sebastian Szczyrba, Bartosz Jabłoński, Dariusz Gąsecki, Piotr Kraszewski, Adam Wyszomirski, Robert Kowalski, Wioletta Kaliszan, Małgorzata Dąbrowska
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
Patients with non-large vessel occlusion acute ischemic stroke (NL-AIS) on oral anticoagulants (OAC) constitute the biggest portion among those who cannot receive any potential-reperfusion treatment even if they appear early in the hospital. We prese
Externí odkaz:
https://doaj.org/article/9b11ec18628e41c7841f35db7f934b84
Publikováno v:
Journal of Education, Health and Sport, Vol 16, Iss 1 (2023)
Introduction and purpose. Andexanet alfa (AA) is a recombinant modified version of human activated factor X. It is used as an antidote for apixsaban and rivaroxaban when reversal of anticoagulation due to life-threatening or uncontrolled bleeding is
Externí odkaz:
https://doaj.org/article/bccc4959d905435aa5dc587f409a557b